Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses

Thomas F. Baumert; Catherine Schuster; François Loïc Cosset; Jean Dubuisson; Maike Hofmann; Norbert Tautz; Mirjam B. Zeisel; Robert Thimme

doi:10.1016/j.jhep.2015.12.021

Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses

Thomas F. Baumert^*, Catherine Schuster, François Loïc Cosset, Jean Dubuisson, Maike Hofmann, Norbert Tautz, Mirjam B. Zeisel, Robert Thimme

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Virologie und Zellbiologie

6 Zitate (Scopus)

Abstract

Following the discovery of the hepatitis C virus (HCV) more than 25 years ago the field has succeeded to develop methods that have changed the safety of blood products, understand the molecular virology, epidemiology and clinical disease of HCV, and identify specific targets for the development of direct-acting antivirals for HCV cure. Nevertheless, major clinical and scientific challenges remain: therapy is still only available to a fraction of infected patients worldwide and many patients remain undiagnosed and/or live in countries where therapy is unattainable. An urgently needed HCV vaccine to eradicate infection remains still elusive. Scientifically, major questions remain regarding the life cycle, pathogenesis and mechanisms of viral clearance and persistence. Addressing these challenges, this meeting report reviews key findings of the 22nd International Symposium on Hepatitis C Virus and Related Viruses in Strasbourg, France from October 9 to 13, 2015.

Originalsprache	Englisch
Zeitschrift	Journal of Hepatology
Jahrgang	64
Ausgabenummer	4
Seiten (von - bis)	968-973
Seitenumfang	6
ISSN	0168-8278
DOIs	https://doi.org/10.1016/j.jhep.2015.12.021
Publikationsstatus	Veröffentlicht - 01.04.2016

Fördermittel

The authors acknowledge grant support of the European Union (ERC-2008-AdG-233130-HEPCENT, FLC and TFB; ERC-2014-AdG-671231-HEPCIR, TFB; EU FP7 HepaMab, TFB, EU-Infect-ERA, TFB and JD; Interreg IV-Rhin Supérieur-FEDER-Hepato-Regio-Net 2012; TFB, RT, MBZ), ANRS (TFB, FLC, JD, CS, MBZ), ANR-10-LABX-0028_HEPSYS (TFB, CS, MBZ), ANR-11-LABX-0048_Ecofect (FLC), Fondation ARC Pour la Recherche (TheraHCC IHUARC IHU201301187, TFB); University of Strasbourg IDEX program W13RATCS (CS), Deutsche Forschungsgemeinschaft (RT, NT).

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

DFG-Fachsystematik

2.21-04 Virologie

Dokumente

10.1016/j.jhep.2015.12.021

Weitere Links

Link to publication in Scopus

Zitieren

@article{6e23051166524308abd1b6b5fd4e7020,

title = "Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses",

abstract = "Following the discovery of the hepatitis C virus (HCV) more than 25 years ago the field has succeeded to develop methods that have changed the safety of blood products, understand the molecular virology, epidemiology and clinical disease of HCV, and identify specific targets for the development of direct-acting antivirals for HCV cure. Nevertheless, major clinical and scientific challenges remain: therapy is still only available to a fraction of infected patients worldwide and many patients remain undiagnosed and/or live in countries where therapy is unattainable. An urgently needed HCV vaccine to eradicate infection remains still elusive. Scientifically, major questions remain regarding the life cycle, pathogenesis and mechanisms of viral clearance and persistence. Addressing these challenges, this meeting report reviews key findings of the 22nd International Symposium on Hepatitis C Virus and Related Viruses in Strasbourg, France from October 9 to 13, 2015.",

author = "Baumert, \{Thomas F.\} and Catherine Schuster and Cosset, \{Fran{\c c}ois Lo{\"i}c\} and Jean Dubuisson and Maike Hofmann and Norbert Tautz and Zeisel, \{Mirjam B.\} and Robert Thimme",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.jhep.2015.12.021",

language = "English",

volume = "64",

pages = "968--973",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses

AU - Baumert, Thomas F.

AU - Schuster, Catherine

AU - Cosset, François Loïc

AU - Dubuisson, Jean

AU - Hofmann, Maike

AU - Tautz, Norbert

AU - Zeisel, Mirjam B.

AU - Thimme, Robert

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Following the discovery of the hepatitis C virus (HCV) more than 25 years ago the field has succeeded to develop methods that have changed the safety of blood products, understand the molecular virology, epidemiology and clinical disease of HCV, and identify specific targets for the development of direct-acting antivirals for HCV cure. Nevertheless, major clinical and scientific challenges remain: therapy is still only available to a fraction of infected patients worldwide and many patients remain undiagnosed and/or live in countries where therapy is unattainable. An urgently needed HCV vaccine to eradicate infection remains still elusive. Scientifically, major questions remain regarding the life cycle, pathogenesis and mechanisms of viral clearance and persistence. Addressing these challenges, this meeting report reviews key findings of the 22nd International Symposium on Hepatitis C Virus and Related Viruses in Strasbourg, France from October 9 to 13, 2015.

AB - Following the discovery of the hepatitis C virus (HCV) more than 25 years ago the field has succeeded to develop methods that have changed the safety of blood products, understand the molecular virology, epidemiology and clinical disease of HCV, and identify specific targets for the development of direct-acting antivirals for HCV cure. Nevertheless, major clinical and scientific challenges remain: therapy is still only available to a fraction of infected patients worldwide and many patients remain undiagnosed and/or live in countries where therapy is unattainable. An urgently needed HCV vaccine to eradicate infection remains still elusive. Scientifically, major questions remain regarding the life cycle, pathogenesis and mechanisms of viral clearance and persistence. Addressing these challenges, this meeting report reviews key findings of the 22nd International Symposium on Hepatitis C Virus and Related Viruses in Strasbourg, France from October 9 to 13, 2015.

UR - https://www.scopus.com/pages/publications/84961918767

U2 - 10.1016/j.jhep.2015.12.021

DO - 10.1016/j.jhep.2015.12.021

M3 - Scientific review articles

C2 - 26780288

AN - SCOPUS:84961918767

SN - 0168-8278

VL - 64

SP - 968

EP - 973

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 4

ER -

Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren